9-ING-41 (Elraglusib) is an ATP-competitive and selective inhibitor of glycogen synthase kinase-3β (GSK-3β), characterized by its maleimide-based structure and an IC50 of 0.71 μM. This compound plays a role in inducing cell cycle arrest, autophagy, and apoptosis in cancer cells, thereby exhibiting anticancer activity. It also holds potential for augmenting the antitumor effects of various chemotherapeutic agents.
- Leads to cell cycle arrest, autophagy, and apoptosis in cancer cells.
- Possesses anticancer activity.
- Potential for enhancing the antitumor effects of chemotherapeutic agents.
- Exhibits single-agent antitumor activity in a mouse model of MCL.